A Phase 3 interventional study of Immunoglobulin G in Severe Sepsis and Septic Shock, sponsored by Green Cross Corporation. Terminated at 17 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-30.
Sponsored by Green Cross Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Shock, Septic with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Korea, Republic of.
Among the 11 studies in Shock, Septic with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2009, is one of 3 in phase 3, and was the 4th registered.
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
Browse Shock, Septic studies →2 of the 11 studies in Shock, Septic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
Asan Medical Center · Sites in Korea, Republic of
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 214 is above the median of 79 across 636 interventional studies indexed under Shock, Septic.
Median enrollment 165 across the 10 interventional studies, 360 across the 1 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Green Cross Corporation, one of the names counted as GC Biopharma Corp.. Under that name alone:
Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
GC Biopharma Corp. has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Septic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07539883Seoul National University Bundang HospitalEffect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study | 2026-12-31 |
| NCT05148286Asan Medical CenterAlbumin and Crystalloid Administration in Septic Shock | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Shock, Septic with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S inj.(Human Immunoglobulin G)' as an Adjuvant Therapy in Adult Subjects with Community-Acquired Severe Sepsis or Septic Shock.
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
This study's planned enrollment of 214 is above the median of 79 across 636 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with severe sepsis or septic shock, if all of the following criteria is satisfied.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
Drug: Immunoglobulin G
The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
Drug: Immunoglobulin G
Immunoglobulin 1.5-2g/Kg/3days
Also known as: GCIV
All cause mortality
Time frame: 28th day
All cause mortality
Time frame: 7th day
Course of SOFA subscores
Time frame: 5 Times: D-1, D1, D3, D5, D7
Laboratory Test
sputum culture test, CBC, blood chemistry, blood coagulation test, CRP, ABGA
Time frame: 7th Day
Duration of ICU and general ward admission
Time frame: 28 days
The record gives a start of Oct 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulin G